NeuroPace (NASDAQ:NPCE) Cut to “Hold” at Wolfe Research

Wolfe Research downgraded shares of NeuroPace (NASDAQ:NPCE – Free Report) from a strong-buy rating to a hold rating in a research report released on Monday morning,Zacks reports.

Other analysts have also recently issued research reports about the stock. Raymond James Financial set a $21.00 price target on shares of NeuroPace in a research note on Tuesday, September 15th. Mizuho decreased their price objective on shares of NeuroPace from $22.00 to $12.00 and set an “outperform” rating for the company in a research report on Monday. Cantor Fitzgerald lowered their price objective on shares of NeuroPace from $21.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday, November 13th. Guggenheim reaffirmed a “neutral” rating on shares of NeuroPace in a report on Wednesday, July 29th. Finally, Leerink Partners downgraded shares of NeuroPace from an “outperform” rating to a “market perform” rating and set a $7.00 target price for the company. in a research note on Friday, November 13th. Five analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $13.11.

Get Our Latest Research Report on NPCE

NeuroPace Price Performance

NASDAQ:NPCE opened at $8.22 on Monday. NeuroPace has a 1-year low of $5.46 and a 1-year high of $19.60. The company has a current ratio of 5.26, a quick ratio of 4.09 and a debt-to-equity ratio of 5.15. The firm has a fifty day simple moving average of $12.81 and a 200 day simple moving average of $14.64. The stock has a market capitalization of $283.18 million, a PE ratio of -14.68 and a beta of 1.98.

Insider Buying and Selling

In other NeuroPace news, CEO Joel Becker purchased 11,891 shares of the company’s stock in a transaction that occurred on Tuesday, November 17th. The shares were acquired at an average price of $8.35 per share, for a total transaction of $99,289.85. Following the purchase, the chief executive officer owned 149,891 shares in the company, valued at approximately $1,251,589.85. The trade was a 8.62% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director R Scott Huennekens purchased 12,500 shares of the business’s stock in a transaction on Wednesday, November 18th. The shares were acquired at an average cost of $8.29 per share, with a total value of $103,625.00. Following the acquisition, the director directly owned 12,500 shares in the company, valued at approximately $103,625. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have acquired 36,282 shares of company stock valued at $302,086. 19.20% of the stock is owned by insiders.

Hedge Funds Weigh In On NeuroPace

Institutional investors and hedge funds have recently modified their holdings of the stock. Legal & General Group Plc bought a new stake in shares of NeuroPace in the second quarter valued at about $41,000. Algert Global LLC grew its stake in shares of NeuroPace by 2.9% in the second quarter. Algert Global LLC now owns 184,774 shares of the company’s stock valued at $2,936,000 after acquiring an additional 5,218 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of NeuroPace in the second quarter valued at about $157,000. Entropy Technologies LP bought a new position in NeuroPace during the third quarter worth about $146,000. Finally, Lazard Asset Management LLC increased its position in NeuroPace by 9.8% during the first quarter. Lazard Asset Management LLC now owns 124,305 shares of the company’s stock worth $1,635,000 after acquiring an additional 11,078 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Key NeuroPace News

Investors following NPCE have been watching these news items:

  • Positive Sentiment: The CEO bought 11,891 shares for about $99,290, the CFO bought 11,891 shares for about $99,171, and a director purchased 12,500 shares for about $103,625. These purchases may signal confidence in NeuroPace’s prospects, though insider buying does not guarantee a stock rebound. CEO SEC filing CFO SEC filing Director SEC filing
  • Neutral Sentiment: Analyst views are mixed: several firms lowered ratings or price targets, while one report cited a substantially higher average target. Price targets are estimates, not guarantees. Analyst coverage and insider buying
  • Negative Sentiment: Recent commentary highlighted weak implant activity, execution challenges and regulatory risks as concerns for NeuroPace’s RNS growth outlook. Wolfe Research downgraded the stock to Hold; other recent rating cuts add pressure to sentiment. Growth and execution risks

About NeuroPace

(Get Free Report)

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.

Further Reading

Analyst Recommendations for NeuroPace (NASDAQ:NPCE)

Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.